Zydus Lifesciences on Monday said it has received approval from US health regulator USFDA to market a generic antifungal medication to treat dandruff, fungal infections, and other skin conditions.
The company has received final approval from the US Food and Drug Administration to manufacture Ketoconazole Shampoo, 2 pc, it said in a statement.
Ketoconazole shampoo is an antifungal medication used to treat dandruff, fungal infections, and other skin conditions.
The product will be produced at the Zydus Group's topical manufacturing site at Changodar, Ahmedabad.
ADVERTISEMENT
As per IQVIA MAT January 2025 data, Ketoconazole shampoo had annual sales of $68.89 mn in the US.
Shares of Zydus Lifesciences were trading 0.22% up at Rs 903.10 apiece on BSE.
ADVERTISEMENT
RECOMMENDED FOR YOU
3G Capital, Singapore's GIC Seek CCI Nod To Acquire Skechers
Jul 02, 2025
Alembic Pharma Shares Surge After USFDA Nod For New Ovarian Cancer Drug
Jun 30, 2025
JB Chemicals Receives USFDA Approval For Drug That Treats Depression Symptoms
Jun 24, 2025
.png?rect=0%2C0%2C3500%2C1969&w=75)
NATCO Pharma's Hyderabad API Manufacturing Facility Gets One Observation From USFDA
Jun 13, 2025
POPULAR
1
UltraTech Denies CCI Probe In Alleged Cement Cartelisation
2
Adani Ports Makes Steel Slag Road In Hazira In Push For Sustainable Reuse Of Industrial Waste
3
India, Maldives Hold Talks To Deepen Trade And Investment Ties
4
Mazagon Dock, Indian Hotels, Solar Industries Could Potentially Be Recognised As Large Cap
5